Radioisotopes in the Treatment of Bone Metastases

2012 ◽  
pp. 787-794
Author(s):  
H. Bulstrode ◽  
J. Buscombe
Keyword(s):  
Bone Metastases

Radioiodide Treatment of Pulmonary Metastases of Differentiated Thyroid Cancer

1979 ◽  
Vol 18 (02) ◽  
pp. 86-90 ◽  
Author(s):  
V. Zamrazil ◽  
D. Pohunková ◽  
S. Röhling ◽  
J. Němec
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastases ◽  
Differentiated Thyroid Cancer ◽  
Pulmonary Metastases ◽  
Survival Rates ◽  
Younger Patients ◽  
131I Uptake ◽  
Young Subjects ◽  
Radioiodide Therapy ◽  
Diagnosis Of Thyroid Cancer

Pulmonary metastases were found in 123 out of 840 patients with thyroid cancer between 1955-1977. 87 patients with pulmonary metastases of differentiated cancer were studied in detail, including an evaluation of prognostically important factors. In 66 of them, the induction of 131I uptake in metastases was attempted, in half of them successfully. Uptake was achieved more frequently in younger subjects, in papillary cancers and in patients with fine pulmonary metastases on chest films. Survival (not corrected for age) was evaluated 10 and 15 years following the diagnosis of thyroid cancer and was found to be 29,1 % and 12,2%, respectively. Significantly higher survival rates were seen in younger patients, in patients with the fine type of pulmonary metastases, in the absence of bone metastases and, particularly, in patients with induced 131I uptake in metastases. Papillary cancers were found to have higher survival rates in males and in young subjects only, in the whole group the survival rates were independent of either microscopic type or sex. It is believed that biologic behaviour of distant (pulmonary) metastases may be influenced by radioiodide therapy.

131J-speichernde pulmonale und ossäre Metastasen differenzierter Schilddrüsenkarzinome bei niedrigem Serum-Thyreoglobulinspiegel – Ausnahme in der Tumornachsorge?

1987 ◽  
Vol 26 (03) ◽  
pp. 139-142 ◽  
Author(s):  
G. Arning ◽  
O. Schober ◽  
H. Hundeshagen ◽  
Ch. Ehrenheim
Keyword(s):  
Serum Level ◽  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Level ◽  
Low Serum

In the follow-up of differentiated thyroid carcinoma it is discussed whether the tumormarker thyroglobulin can replace the1311 scan, especially when the thyroglobulin serum level is normal. A positive1311 scan of metastases in the follow-up of patients with differentiated thyroid carcinoma combined with a low serum thyroglobulin level is extremely rare. The literature shows a frequency of about 4%. Recently we found 3 cases with a positive1311 scan demonstrating pulmonary and bone metastases whereas the serum thyroglobulin level was low.

New models of breast and lung cancer bone metastases for preclinical efficacy testing

2016 ◽  
Author(s):  
Mari I. Suominen ◽  
Urs B. Hagemann ◽  
Yvonne Konkol ◽  
Jenni Bernoulli ◽  
Katja M. Fagerlund ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bone Metastases ◽  
New Models ◽  
Preclinical Efficacy

LIGHT promotes osteolytic bone metastases in NSCLC patients

2016 ◽  
Author(s):  
Giacomina Brunetti ◽  
Dimas Carolina Belisario ◽  
Valentina Alliod ◽  
Lucio Buffoni ◽  
Silvia Colucci ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Nsclc Patients

Molecular imaging of bone metastases using tumor-targeted tracers

2019 ◽  
Vol 63 (2) ◽  
Author(s):  
Najme Karamzade-Ziarati ◽  
Reyhaneh Manafi-Farid ◽  
Bahar Ataeinia ◽  
Werner Langsteger ◽  
Christian Pirich ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Bone Metastases

Bone metastases – 10 years clinicopathologic experience

2018 ◽  
Author(s):  
Panche Zdravkovski ◽  
Panche ['Learta'] ◽  
Vesna Janevska
Keyword(s):  
Bone Metastases
Sign in / Sign up

Export Citation Format

Share Document